Portal hypertension, varices, and transjugular intrahepatic portosystemic shunts

Clinics in Liver Disease

Volumn 4, Issue 1, 2000, Pages 133-150

  Conn, Harold O ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOY; ANTICOAGULANT AGENT; GLYCERYL TRINITRATE; HEPARIN; OCTREOTIDE; ORNIPRESSIN; PLATELET DERIVED GROWTH FACTOR; SOMATOSTATIN; STAINLESS STEEL; TANTALUM; TERLIPRESSIN; TICLOPIDINE; TRAPIDIL; VASOPRESSIN;

ANIMAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECOMPRESSION SURGERY; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGEAL TRANSECTION AND DEVASCULARIZATION; ESOPHAGUS TRANSECTION; ESOPHAGUS VARICES BLEEDING; FILTER; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INSTRUMENTATION; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; STENT; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 0034424967     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(05)70100-8     Document Type: Article

References (65)

1. Improvement of thrombocytopenia due to hypersplenism after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients
2. Transjugular intrahepatic portosystemic shunt for bleeding angiodysplasia-like lesions in portal-hypertensive colopathy
3. Indications forcontraindications to TIPS
4. Prediction of variceal hemorrhage by esophageal endoscopy
5. Drug therapy for variceal hemorrhage
6. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo-controlled trial
7. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis
8. Incidence of large oesophageal varices in patients with cirrhosis: Application to prophylaxis of first bleeding
9. Emergency portacaval shunts in variceal hemorrhage: A critique of critics
10. Transjugular intrahepatic portosystemic shunts (TIPS)
11. Propranolol in the prevention of the first hemorrhage from esophageal varices: Results of a randomized double blind, cooperative clinical trial
12. The treatment of portal hypertension: A meta-analytic review
13. Definitions, methodology and therapeutic strategies in portal hypertension: A consensus development workshop
14. Treatment of TIPS stenosis with ePTFE graft-covered stents
15. A comparison study of self-expandable stents vs balloon angioplasty alone in femoropopliteal artery occlusions
16. Histopathologic analysis of transjugular intrahepatic portosystemic shunts
17. Ticlopidine and antiplatelet therapy
18. The natural history of cirrhosis: I. Survival with esophageal varices
19. Portal hypertension
20. Sodium restriction blunts expansion of plasma volume and ameliorates hyperdynamic circulation in portal hypertension
21. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage
22. Endoscopic sclerotherapy in the management of gastric variceal hemorrhage
23. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension
24. Variceal hemorrhage; pharmacologic approach
25. The course of patients after variceal hemorrhage
26. Sclerotherapy for male alcoholics with cirrhosis who have bled from esophageal varices: Results of a randomized multicenter trial
27. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems
28. Transjugular intrahepatic portosystemic shunt stenosis and revision: Early and midterm results
29. Transjugular intrahepatic portosystemic shunt procedure: Efficacy of 10-mm versus 12-mm Wallstents
30. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy
31. Histopathologic study of stenotic and occluded transjugular intrahepatic portosystemic shunts
32. Creation of transjugular intrahepatic portosystemic shunts with the Wallstent endoprosthesis: Results in 100 patients
33. Incidence of shunt occlusion or stenosis following transjugular intrahepatic portosystemic shunt placement
34. Transjugular intrahepatic portosystemic shunt: Short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis
35. Induction of PDGF-responsive genes in vascular smooth muscle. Implications for the early response to vessel injury
36. Treatment of Budd-Chiari syndrome by metallic stent as a bridge to liver transplantation
37. Effects of TIPS on ascites and related complications
38. A new approach to the treatment of atherosclerosis and trapidil as an antagonist to platelet-derived growth factor
39. Treatment of bleeding esophagogastric varices due to extrahepatic portal hypertension: Results of portal-systemic shunts during 35 years
40. The transjugular intrahepatic portosystemic stentshunt (TIPSS): A new nonoperative, transjugular percutaneous procedure
41. Transjugular portal venography and radiologic portacaval shunt. An experimental study
42. A prospective trial of transjugular intrahepatic portasystemic stent shunts versus small-diameter prosthetic H-graft portacaval shunts in the treatment of bleeding varices
43. Platelet-derived growth factor
44. TIPS: Technical aspects and clinical results
45. The implantation and maintenance of TIPS: Rules of the road and tricks of the trade
46. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding
47. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): State of the art
48. Clinical outcome of 100 patients after transjugular intrahepatic portosystemic shunt (TIPS) for variceal hemorrhage
49. Hemolytic anemia following TIPS
50. Development of pseudointima and stenosis after transjugular intrahepatic portasystemic shunts: Characterization of cell phenotype and function
51. The hematological consequences of transjugular intra-hepatic portosystemic shunts
52. Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: A randomized trial
53. Stenosis and occlusion after TIPS: Prevention and correction
54. Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts: Comparative histopathologic analysis in humans and swine
55. Complications of TIPS implantation
56. Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: A randomized study comparing trapidil plus ticlopidine with heparin treatment
57. Transjugular intrahepatic portosystemic shunt (TIPS). Thrombogenicity in stents and its effect on shunt patency
58. Transjugular intrahepatic-portasystemic stent shunting for control of acute and recurrent upper gastrointestinal haemorrhage related to portal hypertension
59. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind randomized, placebo-controlled trial
60. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: Incidence and risk factors
61. Endoscopic ligation of esophageal varices
62. m-labeled human serum albumin
63. Transjugular intrahepatic portosystemic shunt with silicone-covered Wallstents: Results in a swine model
64. Transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites: Effect on body weight and Child-Pugh score